

## Highlights of This Issue 5839

### SPECIAL FEATURES

#### CCR Translations

- 5841 **Better Late than Early: FDG-PET Imaging in Metastatic Renal Cell Carcinoma**  
Michael R. Harrison and Daniel J. George  
*See article p. 6021*

#### Molecular Pathways

- 5844 **Potential Prostate Cancer Drug Target: Bioactivation of Androstenediol by Conversion to Dihydrotestosterone**  
James L. Mohler, Mark A. Titus, and Elizabeth M. Wilson
- 5850 **ERK1/2 and p38 $\alpha$ / $\beta$  Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease**  
Maria Soledad Sosa, Alvaro Avivar-Valderas, Paloma Bragado, Huei-Chi Wen, and Julio A. Aguirre-Ghiso

#### Review

- 5858 **Thrombotic Microangiopathy with Targeted Cancer Agents**  
John A. Blake-Haskins, Robert J. Lechleider, and Robert J. Kreitman

#### HUMAN CANCER BIOLOGY

- 5867 **Resection of Non-Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System**  
Andrew V. Kossenkov, Anil Vachani, Celia Chang, Calen Nichols, Shere Billouin, Wenhwai Horng, William N. Rom, Steven M. Albelda, Michael K. Showe, and Louise C. Showe

- 5878 **ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy**  
Sarah Minner, Malaika Enodien, Hüseyin Sirma, Andreas M. Luebke, Antje Krohn, Pascale S. Mayer, Ronald Simon, Pierre Tennstedt, Julia Müller, Laura Scholz, Jan C. Brase, Alvin Y. Liu, Hartmut Schlüter, Klaus Pantel, Udo Schumacher, Carsten Bokemeyer, Thomas Steuber, Markus Graefen, Guido Sauter, and Thorsten Schlomm

- 5889 **Characterization of a Cleavage Stimulation Factor, 3' pre-RNA, Subunit 2, 64 kDa (CSTF2) as a Therapeutic Target for Lung Cancer**  
Masato Aragaki, Koji Takahashi, Hirohiko Akiyama, Eiju Tsuchiya, Satoshi Kondo, Yusuke Nakamura, and Yataro Daigo

#### CANCER THERAPY: PRECLINICAL

- 5901 **Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma**  
Xianbiao Xie, Markus P.H. Ghadimi, Eric D. Young, Roman Belousov, Quan-sheng Zhu, Juehui Liu, Gonzalo Lopez, Chiara Colombo, Tingsheng Peng, David Reynoso, Jason L. Hornick, Alexander J. Lazar, and Dina Lev
- 5913 **Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants**  
Elahe A. Mostaghel, Brett T. Marck, Stephen R. Plymate, Robert L. Vessella, Stephen Balk, Alvin M. Matsumoto, Peter S. Nelson, and R. Bruce Montgomery
- 5926 **Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody**  
Xing Du, Laiman Xiang, Crystal Mackall, and Ira Pastan
- 5935 **Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel *In Vivo* Model of Acquired Cetuximab Resistance**  
Kelly M. Quesnelle and Jennifer R. Grandis

5945 **Targeting Human B-cell Malignancies through Ig Light Chain-Specific Cytotoxic T Lymphocytes**

Jinsheng Weng, Soung-Chul Cha, Satoko Matsueda, Gheath Alatrash, Michael S. Popescu, Qing Yi, Jeffrey J. Molldrem, Michael Wang, Sattva S. Neelapu, and Larry W. Kwak

5953 **Curcumin Treatment Suppresses IKK $\beta$  Kinase Activity of Salivary Cells of Patients with Head and Neck Cancer: A Pilot Study**

Suejung G. Kim, Mysore S. Veena, Saroj K. Basak, Eugene Han, Tracey Tajima, David W. Gjertson, Joshua Starr, Ofer Eidelman, Harvey B. Pollard, Meera Srivastava, Eri S. Srivatsan, and Marilene B. Wang

5962 **Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor**

Niels Jørgen Østergaard Skartved, Helle Jane Jacobsen, Mikkel Wandahl Pedersen, Pernille Foged Jensen, Jette Wagtberg Sen, Thomas Kjærsgaard Jørgensen, Adam Hey, and Michael Kragh

5973 **ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2<sup>high</sup>/Mcl-1<sup>low</sup> Profile and Synergizes with Other Antineoplastic Agents**

Cyrille Touzeau, Christelle Dousset, Linda Bodet, Patricia Gomez-Bougie, Stéphanie Bonnaud, Anne Moreau, Philippe Moreau, Catherine Pellat-Deceunynck, Martine Amiot, and Steven Le Gouill

## IMAGING, DIAGNOSIS, PROGNOSIS

5982 **Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials**

AeRang Kim, Eva Dombi, Jeffrey Solomon, Elizabeth Fox, Frank M. Balis, and Brigitte C. Widemann

5991 **A Polymorphic -844T/C in FasL Promoter Predicts Survival and Relapse in Non-Small Cell Lung Cancer**

Wen-Wei Sung, Yao-Chen Wang, Ya-Wen Cheng, Ming-Ching Lee, Kun-Tu Yeh, John Wang, Chih-Yi Chen, and Huei Lee

6000 **Specific PET Imaging of x<sub>C</sub><sup>-</sup> Transporter Activity Using a <sup>18</sup>F-Labeled Glutamate Derivative Reveals a Dominant Pathway in Tumor Metabolism**

Norman Koglin, Andre Mueller, Mathias Berndt, Heribert Schmitt-Willich, Luisella Toschi, Andrew W. Stephens, Volker Gekeler, Matthias Friebe, and Ludger M. Dinkelborg

6012 **A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors**

Martin Filipits, Margaretha Rudas, Raimund Jakesz, Peter Dubsky, Florian Fitzal, Christian F. Singer, Otto Dietze, Richard Greil, Andrea Jelen, Paul Sevelda, Christa Freibauer, Volkmar Müller, Fritz Jänicke, Marcus Schmidt, Heinz Kölbl, Achim Rody, Manfred Kaufmann, Werner Schroth, Hiltrud Brauch, Matthias Schwab, Peter Fritz, Karsten E. Weber, Inke S. Feder, Guido Hennig, Ralf Kronenwett, Mathias Gehrmann, and Michael Gnant, for the EP Investigators

6021 **Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer**

Irfan Kayani, Norbert Avril, Jamshed Bomanji, Simon Chowdhury, Andrea Rockall, Anju Sahdev, Paul Nathan, Peter Wilson, Jonathan Shamash, Kevin Sharpe, Louise Lim, John Dickson, Peter Ell, Andrew Reynolds, and Thomas Powles

*See commentary p. 5841*

6029 **Prognostic Impact of  $\Delta$ TAp73 Isoform Levels and Their Target Genes in Colon Cancer Patients**

Beatriz Soldevilla, Raquel Díaz, Javier Silva, Yolanda Campos-Martín, Concepción Muñoz, Vanesa García, José M García, Cristina Peña, Mercedes Herrera, Marta Rodriguez, Irene Gómez, Nagat Mohamed, Margarita M. Marques, Félix Bonilla, and Gemma Domínguez

6040 **Upregulation of Rac GTPase-Activating Protein 1 Is Significantly Associated with the Early Recurrence of Human Hepatocellular Carcinoma**

Suk Mei Wang, London Lucien P.J. Ooi, and Kam M. Hui

## CANCER THERAPY: CLINICAL

6052 **Phase I Trial of Cixutumumab Combined with Temozolomide in Patients with Advanced Cancer**

Aung Naing, Razelle Kurzrock, Angelika Burger, Sachin Gupta, Xiudong Lei, Naifa Busaidy, David Hong, Helen X. Chen, Lawrence A. Doyle, Lance K. Heilbrun, Eric Rohren, Chuan Ng, Chandtip Chandhasin, and Patricia LoRusso

6061 **Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing**

Christina I. Herold, Vijaya Chadaram, Bercedis L. Peterson, P. Kelly Marcom, Judith Hopkins, Gretchen G. Kimmick, Justin Favaro, Erika Hamilton, Renee A. Welch, Sarah Bacus, and Kimberly L. Blackwell

6071 **Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors**

Stijn L.W. Koolen, Petronella O. Witteveen, Robert S. Jansen, Marlies H.G. Langenberg, Roelien H. Kronemeijer, Annemarie Nol, Ignacio Garcia-Ribas, Sophie Callies, Karim A. Benhadji, Christopher A. Slapak, Jos H. Beijnen, Emile E. Voest, and Jan H.M. Schellens

6083 **Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer**

Jermaine Coward, Hagen Kulbe, Probir Chakravarty, David Leader, Vessela Vassileva, D. Andrew Leinster, Richard Thompson, Tiziana Schioppa, Jeffery Nemeth, Jessica Vermeulen, Naveena Singh, Norbert Avril, Jeff Cummings, Elton Rexhepaj, Karin Jirstrom, William M. Gallagher, Donal J. Brennan, Iain A. McNeish, and Frances R. Balkwill


**PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE**

6097 **Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C<sub>18</sub>-Ceramide as a Novel Biomarker for Monitoring Response**

Sahar A. Saddoughi, Elizabeth Garrett-Mayer, Uzair Chaudhary, Paul E. O'Brien, Larry B. Afrin, Terry A. Day, M. Boyd Gillespie, Anand K. Sharma, Christina S. Wilhoit, Robin Bostick, Can E. Senkal, Yusuf A. Hannun, Jacek Bielawski, George R. Simon, Keisuke Shirai, and Besim Ogretmen

**ABOUT THE COVER**

Interleukin-6 (IL-6) has tumor-promoting actions on both malignant and stromal cells in a range of experimental cancer models. In addition, high plasma IL-6 levels are associated with poor prognosis in ovarian cancer, but there is little information as to the source of this IL-6. Ovarian cancer biopsies were stained for IL-6 (left) and automated algorithms used to assess both malignant (right) and stromal (middle) compartments. Expression levels were quantified using an autoscore that combined both the intensity and density of positive pixels. IL-6 staining was seen in both the malignant and nonmalignant cells, but was significantly higher in the malignant cell areas. For further details, see Coward and colleagues on page 6083 of this issue.



# Clinical Cancer Research

**17 (18)**

*Clin Cancer Res* 2011;17:5839-6105.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/17/18>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/17/18>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.